XOMA Royalty (XOMA) Total Liabilities (2010 - 2026)
XOMA Royalty's (XOMA) quarterly Total Liabilities came in at $159.0 million in Q1 2026, up 24.07% year-on-year from $128.1 million in Q1 2025, and down 5.79% quarter-over-quarter from $168.7 million in Q4 2025.
XOMA Royalty (XOMA) Total Liabilities (2010 - 2026) Analysis & Trends
XOMA Royalty has disclosed Total Liabilities across 17 years of filings, most recently posting $159.0 million for Q1 2026.
- Total Liabilities for Q1 2026 came in at $159.0 million, up 24.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $159.0 million (up 24.07% YoY), and the FY2025 annual result was $168.7 million, up 21.08% from the prior year.
- Total Liabilities came in at $159.0 million for Q1 2026 at XOMA Royalty, down from $168.7 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $168.7 million in Q4 2025 to a low of $15.5 million in Q2 2023.
- The 5-year median for Total Liabilities is $131.0 million (2025), against an average of $92.3 million.
- Across the five-year window, Total Liabilities plunged 49.61% in 2022 and jumped 822.23% in 2024, its largest moves.
- XOMA Royalty's Total Liabilities stood at $16.4 million in 2022, then soared by 789.42% to $145.6 million in 2023, then declined by 4.28% to $139.4 million in 2024, then climbed by 21.08% to $168.7 million in 2025, then decreased by 5.79% to $159.0 million in 2026.
- The last three Total Liabilities figures came in at $159.0 million (Q1 2026), $168.7 million (Q4 2025), and $155.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | 1.74 Mn |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | 15.48 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 731.60 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 19.51 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | 10.44 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 943,068.00 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 7.12 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 137.56 Mn |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - | 158.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 158.96 Mn |
| Dec 31, 2025 | 168.74 Mn |
| Sep 30, 2025 | 155.19 Mn |
| Jun 30, 2025 | 131.00 Mn |
| Mar 31, 2025 | 128.12 Mn |
| Dec 31, 2024 | 139.36 Mn |
| Sep 30, 2024 | 138.53 Mn |
| Jun 30, 2024 | 143.29 Mn |
| Mar 31, 2024 | 137.08 Mn |
| Dec 31, 2023 | 145.58 Mn |
| Sep 30, 2023 | 18.13 Mn |
| Jun 30, 2023 | 15.54 Mn |
| Mar 31, 2023 | 19.14 Mn |
| Dec 31, 2022 | 16.37 Mn |
| Sep 30, 2022 | 15.81 Mn |
| Jun 30, 2022 | 19.27 Mn |
| Mar 31, 2022 | 19.24 Mn |
| Dec 31, 2021 | 24.69 Mn |
| Sep 30, 2021 | 18.92 Mn |
| Jun 30, 2021 | 19.17 Mn |